$5250 | Single User
$6250 | Site License
$8450 | Enterprise License

Depression Drugs Market: By Medication Class (Monoamine Oxidase Inhibitors (MAOIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), Anticonvulsants, Beta-Blockers, Benzodiazepines, Others); By Brand (Celexa, Zoloft, Cymbalta, Prozac, Paxil, Others)-Forecast (2016-2021) [Report Updated: 25-02-2016]

Published by Industry ARC: 25 Feb 2016 | 80272 | In Stock

Introduction

Depression is a mood disorder that causes relentless feeling of sadness. Many factors causes depression, including brain biology and chemistry, genetics and life events such as trauma, complicated relationships, childhood experiences, loss of a loved one and any stressful situation.

The symptoms of depression are often treated by several types of medications, also known as antidepressant drugs. The most common antidepressant drugs used to treat depression are Celexa, Zoloft, Cymbalta, Prozac, Paxil, Lexapro and Pristiq.

The global depression drugs market is growing due to rising awareness about different types of depression and their treatment. In addition, rising geriatric population, growing numbers of patients suffering from depression in developed countries such as U.S. and Canada, are also supporting to the growth of the market. However, stringent regulations for the approval of antidepressants, patent expiry of several blockbuster antidepressants drugs and strict regulations for the commercial usage of antidepressants without prescription are some of the major restraints hamper the growth of the global depression drugs market.


The global depression drugs market is segmented based on various depression medication classes, brand and geography. Based on the depression medication classes, the market is sub-segmented into monoamine oxidase inhibitors (MAOIs), serotonin-norepinephrine reuptake inhibitors (SNRI), anticonvulsants, beta-blockers, tetracyclic antidepressants (TeCAs), benzodiazepines, selective serotonin reuptake inhibitors (SSRIs) and others. Amongst the medication classes, SNRI is the highest revenue segment in the current scenario.

On the basis of brand, the global depression drugs market is bifurcated into Celexa, Zoloft, Cymbalta, Prozac, Paxil, Lexapro, Pristiq and others. From the geographical perspectives, the market is segmented in North America (USA, Mexico and Canada), Europe (U.K., Germany, France, Spain, Italy and Rest of Europe), Asia Pacific (Japan, India, China, Australia and Rest of Asia Pacific) and Rest of the World (Middle East, Latin America and Africa). North America, followed by Europe, holds major market share in the global depression drugs market due to presence of large population base suffering from various types of depression. Asia Pacific is expected to grow at a moderate growth rate during the forecast period due to increasing investment by several drug manufacturing companies owing to low wages, minimal investment, large population base and availability of skilled labour.


The dominant players in the Depression Drugs Market are:

Novartis International AG

Abbott Laboratories

Allergan, Plc

Janssen Pharmaceuticals, Inc.

Lupin Pharmaceuticals, Inc.

Table of Contents
for Depression Drugs Market: By Medication Class (Monoamine Oxidase Inhibitors (MAOIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), Anticonvulsants, Beta-Blockers, Benzodiazepines, Others); By Brand (Celexa, Zoloft, Cymbalta, Prozac, Paxil, Others)-Forecast (2016-2021) [Report Updated: 25-02-2016]

  • 1. Depression Drugs Market Overview

    2. Executive Summary

    3. Depression Drugs - Market Landscape

    3.1. Market Share Analysis

    3.2. Comparative Analysis

    3.2.1. Product Benchmarking

    3.2.2. End user profiling

    3.2.3. Patent Analysis

    3.2.4. Top 5 Financials Analysis

    4. Depression Drugs - Market Forces

    4.1. Market Drivers

    4.1.1. Rising Awareness about Different Types of Depression

    4.1.2. Rising Geriatric Population

    4.1.3. Increasing Incidences of Depression

    4.2. Market Constraints

    4.2.1. Stringent Regulations for the Approval of Antidepressants

    4.2.2. Strict Regulations for the Commercial Usage of Antidepressants without prescription

    4.2.3. Patent Expiry of Several Blockbuster Antidepressant Drugs

    4.3. Market Challenges

    4.3.1. Narrow Drug Pipelines

    4.4. Attractiveness of the Industry

    4.4.1. Power of Suppliers

    4.4.2. Power of Customers

    4.4.3. Threat of New entrants

    4.4.4. Threat of Substitution

    4.4.5. Degree of Competition

    5. Depression Drugs Market– Strategic Analysis

    5.1. Value Chain Analysis

    5.2. Pricing Analysis

    5.3. Opportunities Analysis

    6. Depression Drugs Market – By Medication Class

    6.1. Monoamine Oxidase Inhibitors (MAOIs)

    6.2. Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)

    6.3. Anticonvulsants

    6.4. Beta-Blockers

    6.5. Tetracyclic Antidepressants (TeCAs)

    6.6. Benzodiazepines

    6.7. Selective Serotonin Reuptake Inhibitors (SSRIs)

    7. Depression Drugs Market – By Brand

    7.1. Celexa

    7.2. Zoloft

    7.3. Cymbalta

    7.4. Prozac

    7.5. Paxil

    7.6. Lexapro

    7.7. Prestiq

    7.8. Others

    8. Depression Drugs Market - Geographical Analysis

    8.1. Introduction

    8.2. North America

    8.2.1. USA

    8.2.2. Mexico

    8.2.3. Canada

    8.3. Europe

    8.3.1. Germany

    8.3.2. France

    8.3.3. U.K.

    8.3.4. Italy

    8.3.5. Spain

    8.3.6. Rest of Europe

    8.4. APAC

    8.4.1. China

    8.4.2. India

    8.4.3. Japan

    8.4.4. Australia

    8.4.5. Rest of APAC

    8.5. Rest of the World (RoW)

    9. Market Entropy

    9.1. New Product Launches

    9.2. Mergers and Acquisitions,

    9.3. Collaborations, JVs and Partnerships

    10. Company Profiles (Overview, Financials, SWOT Analysis – Top 05 Companies, Developments and Product Portfolio)

    10.1. Novartis International AG

    10.2. Janssen Pharmaceuticals, Inc.

    10.3. Lupin Pharmaceuticals, Inc.

    10.4. Abbott Laboratories

    10.5. Allergan, Plc

    10.6. MSI Methylation Sciences Inc.

    10.7. Luye Pharma Group Ltd.

    10.8. H. Lundbeck A/S

    *More than 40 Companies are profiled in this Research Report, Complete List available on Request*

    "*Financials would be provided on a best efforts basis for private companies"

    11. Appendix

    11.1. Abbreviations

    11.2. Sources

    11.3. Research Methodology

    11.4. Bibliography

    11.5. Compilation of Expert Insights

    11.6. Disclaimer

List Of Tables
in Depression Drugs Market: By Medication Class (Monoamine Oxidase Inhibitors (MAOIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), Anticonvulsants, Beta-Blockers, Benzodiazepines, Others); By Brand (Celexa, Zoloft, Cymbalta, Prozac, Paxil, Others)-Forecast (2016-2021) [Report Updated: 25-02-2016]

No

Additional Details

Publisher

Industry ARC

Publisher Information

IndustryARC is the Leading Provider of Market Research Reports, Custom Consulting Services, Data Analytics and Industry Analysis. Our goal is to provide the right information required by the stakeholder at the right point of time, in a format which assists an intelligent and informed decision making process!



We provide profound information with a proactive collaboration with the clients to identify new opportunities and guide them to find the best strategy for finding growth avenues. Our in-depth Research Reports with analysis done by experienced consultants and inputs from industry experts, Key Opinion Leaders (KOLs) span multiple sectors such as:

Reference

80272 | HCR 0242

Report Format

PDF

Industry ARC Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Depression Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,495 More Info
Global Depression Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Electroceuticals/Bioelectric Medicine Market by Product (Pacemakers, Cochlear Implants, Spinal Cord Stimulators), Type of Device (Implantable, Non-Invasive), Application (Arrhythmia, Depression, Migraine), End User (Hospitals) - Global Forecast to 2021
The global electroceuticals/bioelectric medicine market is expected to reach USD 25.20 billion by 20...
06 Jun 2016 by MarketsandMarkets USD $5,650 More Info
Global Depression Therapy & Treatment Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 – 2022
Depression treatment market is segmented on the basis of antidepressants drugs, devices and therapie...
25 Feb 2016 by Occams Business Research USD $3,900 More Info
Global Depression Therapy & Treatment Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 – 2022
Depression treatment market is segmented on the basis of antidepressants drugs, devices and therapie...
25 Feb 2016 by Occams Business Research USD $5,900 More Info
Treatment Resistant Depression Global Clinical Trials Review, H2, 2015
Treatment Resistant Depression Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical t...
23 Dec 2015 by Global Data USD $2,500 More Info
Psychotic Major Depression Global Clinical Trials Review, H2, 2015
Psychotic Major Depression Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial...
16 Dec 2015 by Global Data USD $2,500 More Info
Post Partum Depression (Maternal Depression / Postnatal Depression) Global Clinical Trials Review, H2, 2015
Post Partum Depression (Maternal Depression / Postnatal Depression) Global Clinical Trials Review, H...
04 Dec 2015 by Global Data USD $2,500 More Info
Neuromodulation Market by Technology (Deep Brain Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation) & by Application (Depression, Parkinson’s, Tinnitus, Alzheimer’s, Epilepsy, Ischemia, Obesity) - Trends & Global Forecast to 2020
Over the years, the global healthcare industry has witnessed a paradigm shift, and is now increasing...
02 Jul 2015 by MarketsandMarkets USD $5,650 More Info
Physician Views: Can Lundbeck and Otsuka's newly approved Rexulti compete with branded and generic competition in the schizophrenia and depression markets?
ScopeFDA approval of Lundbeck and Otsuka Pharmaceuticals' Rexulti – which was announced last week – ...
01 Jul 2015 by FirstWord Pharma USD $695 More Info

This report is published by Industry ARC

IndustryARC is the Leading Provider of Market Research Reports, Custom Consulting Services, Data Analytics and Industry Analysis. Our goal is to provide the right information required by the stakeholder at the right point of time, in a format which assists an intelligent and informed decision making process!

We provide profound information with a proactive collaboration with the clients to identify new opportunities and guide them to find the best strategy for finding growth avenues. Our in-depth Research Reports with analysis done by experienced consultants and inputs from industry experts, Key Opinion Leaders (KOLs) span multiple sectors such as:

Download Free Report Summary PDF

Depression Drugs Market: By Medication Class (Monoamine Oxidase Inhibitors (MAOIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), Anticonvulsants, Beta-Blockers, Benzodiazepines, Others); By Brand (Celexa, Zoloft, Cymbalta, Prozac, Paxil, Others)-Forecast (2016-2021) [Report Updated: 25-02-2016] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data